Skip to main content
. 2023 Jan 31;11(2):e03002-22. doi: 10.1128/spectrum.03002-22

TABLE 2.

Antibiotic resistance profiles of the string test-positive isolatesa

Strain MIC (μg/ML) (resistance phenotype)
MERO AMIK GEN ATM CIP P/T4 AUGC C/T COL FOT TGC SXT TOB TAZ CZA IMI ETP
AB527 16 (R) >32 (R) >8 (R) 16 (R) >2 (R) >32/4 (R) >64/2 (R) 16/4 (R) 2 (S) >8 (R) 0.5 (S) <1/19 (S) >8 (R) >16 (R) 8/4 (R) >16 (R) >2 (R)
AB489 >16 (R) 8 (I) >8 (R) >32 (R) >2 (R) >32/4 (R) >64/2 (R) >32/4 (R) 1 (S) >8 (R) 1 (S) >8/152 (R) >8 (R) >16 (R) >16/4 (R) 16 (R) >2 (R)
ABF246 >16 (R) >32 (R) >8 (R) >32 (R) >2 (R) >32/4 (R) >64/2 (R) >32/4 (R) 1 (S) >8 (R) 1 (S) >8/152 (R) >8 (R) >16 (R) >16/4 (R) >16 (R) >2 (R)
AB167 >16 (R) 8 (I) >8 (R) >32 (R) >2 (R) >32/4 (R) >64/2 (R) >32/4 (R) 2 (S) >8 (R) 1 (S) >8/152 (R) 8 (R) >16 (R) >16/4 (R) 16 (R) >2 (R)
AB190 >16 (R) >32 (R) >8 (R) 16 (R) >2 (R) >32/4 (R) >64/2 (R) 16/4 (R) 0.5 (S) >8 (R) 0.5 (S) >8/152 (R) >8 (R) >16 (R) 8/4 (R) 8 (R) >2 (R)
AB378 >16 (R) >32 (R) >8 (R) >32 (R) >2 (R) >32/4 (R) >64/2 (R) >32/4 (R) 0.5 (S) >8 (R) 0.5 (S) >8/152 (R) 8 (R) >16 (R) >16/4 (R) >16 (R) >2 (R)
AB925 4 (I) 8 (I) >8 (R) >32 (R) >2 (R) >32/4 (R) >64/2 (R) 16/4 (R) 1 (S) 4 (R) 0.5 (S) >8/152 (R) 4 (I) >16 (R) >1/4 (R) >16 (R) >2 (R)
AB4616 16 (R) 8 (I) 0.5 (S) >32 (R) >2 (R) >32/4 (R) >64/2 (R) >32/4 (R) 1 (S) >8 (R) 0.5 (S) <1/19 (S) 1 (S) >16 (R) >16/4 (R) 4 (I) >2 (R)
ABD267 >16 (R) 4 (S) >8 (R) >32 (R) >2 (R) >32/4 (R) >64/2 (R) >32/4 (R) 2 (S) >8 (R) 1 (S) >8/152 (R) >8 (R) >16 (R) >16/4 (R) 16 (R) >2 (R)
a

MERO, meropenem; AMIK, amikacin; GEN, gentamicin; ATM, aztreonam; CIP, ciprofloxacin; P/T4, piperacillin/tazobactam constant 4; AUGC, amoxicillin/clavulanic acid constant 2; C/T, ceftolozane-tazobactam; COL, colistin; FOT, cefotaxime; TGC, tigecycline; SXT, trimethoprim-sulfamethoxazole; TOB, tobramycin; TAZ, tazobactam; CZA, ceftazidime-avibactam; IMI, imipenem; ETP, ertapenem; R, resistant; S, susceptible; I, intermediately resistant.